Form 4: Director Mohammad Hirmand Receives Stock Options

Director Mohammad Hirmand of Whitehawk Therapeutics, Inc. was granted 38,040 stock options with an exercise price of $4.16.

Summary

• Mohammad Hirmand, a Director at Whitehawk Therapeutics, Inc., received a grant of 38,040 stock options.
• The options have an exercise price of $4.16 per share.
• The grant date is June 12, 2026, with an expiration date of June 12, 2036.
• The options vest in full on the earlier of the one-year anniversary of the grant or the day before the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director remaining a Service Provider to the company.

Future Outlook

The options vest fully within one year, incentivizing the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership retention and alignment with long-term performance goals.

Comparison to Industry Standards

• The use of a one-year vesting schedule is consistent with standard equity incentive plans for non-employee directors in small-cap biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 12, 2027, or the day prior to the next annual meeting of stockholders.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Form 4, Insider Trading, Stock Options, Director Compensation